Emergent Operating Income from 2010 to 2024

EBS Stock

USD 6.67 1.11 19.96%

Emergent Biosolutions Operating Income yearly trend continues to be comparatively stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Emergent Biosolutions generates from its operations. View All Fundamentals

Operating Income

First Reported

2004-03-31

Previous Quarter

-41.9 M

Current Value

39.8 M

Quarterly Volatility

70.6 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Emergent Biosolutions financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Emergent Biosolutions' main balance sheet or income statement drivers, such as Depreciation And Amortization of 158.9 M, Interest Expense of 45 M or Total Revenue of 1.4 B, as well as many indicators such as Price To Sales Ratio of 0.11, Dividend Yield of 0.018 or PTB Ratio of 0.18. Emergent financial statements analysis is a perfect complement when working with Emergent Biosolutions Valuation or Volatility modules.

Check out the analysis of Emergent Biosolutions Correlation against competitors.

For more information on how to buy Emergent Stock please use our How to Invest in Emergent Biosolutions guide.

Latest Emergent Biosolutions' Operating Income Growth Pattern

Below is the plot of the Operating Income of Emergent Biosolutions over the last few years. Operating Income is the amount of profit realized from Emergent Biosolutions operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Emergent Biosolutions is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Emergent Biosolutions' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Emergent Biosolutions' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Operating Income

Timeline

Emergent Operating Income Regression Statistics

	Arithmetic Mean	62,696,733
	Geometric Mean	73,500,271
	Coefficient Of Variation	274.43
	Mean Deviation	116,969,182
	Median	58,056,000
	Standard Deviation	172,057,599
	Sample Variance	29603.8T
	Range	624.7M
	R-Value	(0.11)
	Mean Square Error	31486.8T
	R-Squared	0.01
	Significance	0.69
	Slope	(4,278,364)
	Total Sum of Squares	414453.4T

Emergent Operating Income History

	2024	-181.4 M
	2023	-190.9 M
	2022	-166 M
	2021	352.6 M
	2020	433.8 M
	2019	114.1 M
	2018	89.8 M

Other Fundumenentals of Emergent Biosolutions

Non Operating Income Net Other

Emergent Biosolutions Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Current Deferred Revenue	Long Term Debt	Short Term Investments	Property Plant Equipment	Deferred Long Term Liab	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.97	0.88	0.75	0.53	0.44	0.62	0.99	0.77	0.72	0.79	0.64	0.53	0.69	0.93	0.98	0.9	-0.87	0.9	0.78	0.91	0.2	0.68	0.85	-0.19	-0.6
Total Stockholder Equity	0.97		0.75	0.7	0.46	0.42	0.52	0.92	0.69	0.62	0.66	0.56	0.6	0.69	0.87	0.97	0.87	-0.82	0.92	0.76	0.91	0.09	0.66	0.83	-0.05	-0.52
Net Debt	0.88	0.75		0.64	0.5	0.48	0.7	0.93	0.7	0.76	0.89	0.7	0.28	0.59	0.91	0.83	0.81	-0.8	0.71	0.69	0.79	0.3	0.45	0.74	-0.44	-0.62
Retained Earnings	0.75	0.7	0.64		0.81	0.53	0.72	0.76	0.98	0.62	0.8	0.74	0.58	0.45	0.75	0.73	0.7	-0.78	0.77	0.55	0.71	0.22	0.75	0.73	-0.04	-0.51
Accounts Payable	0.53	0.46	0.5	0.81		0.79	0.92	0.56	0.81	0.24	0.79	0.93	0.69	0.62	0.67	0.42	0.53	-0.45	0.71	0.63	0.65	0.1	0.6	0.64	0.23	-0.05
Net Receivables	0.44	0.42	0.48	0.53	0.79		0.88	0.45	0.54	-0.06	0.72	0.85	0.69	0.77	0.64	0.34	0.48	-0.23	0.63	0.76	0.6	-0.32	0.15	0.57	0.4	0.08
Good Will	0.62	0.52	0.7	0.72	0.92	0.88		0.67	0.76	0.28	0.92	0.98	0.62	0.73	0.79	0.49	0.63	-0.46	0.72	0.76	0.72	0.03	0.42	0.69	0.1	-0.13
Total Liab	0.99	0.92	0.93	0.76	0.56	0.45	0.67		0.8	0.77	0.84	0.68	0.47	0.67	0.94	0.95	0.89	-0.87	0.85	0.77	0.88	0.26	0.66	0.84	-0.27	-0.63
Total Current Assets	0.77	0.69	0.7	0.98	0.81	0.54	0.76	0.8		0.67	0.84	0.76	0.51	0.45	0.76	0.73	0.69	-0.78	0.75	0.56	0.71	0.25	0.73	0.71	-0.14	-0.56
Short Term Debt	0.72	0.62	0.76	0.62	0.24	-0.06	0.28	0.77	0.67		0.57	0.34	-0.07	0.05	0.59	0.76	0.56	-0.88	0.5	0.19	0.57	0.62	0.63	0.47	-0.76	-0.79
Intangible Assets	0.79	0.66	0.89	0.8	0.79	0.72	0.92	0.84	0.84	0.57		0.89	0.49	0.65	0.91	0.69	0.77	-0.67	0.73	0.74	0.77	0.15	0.45	0.76	-0.16	-0.47
Common Stock	0.64	0.56	0.7	0.74	0.93	0.85	0.98	0.68	0.76	0.34	0.89		0.6	0.7	0.8	0.54	0.65	-0.55	0.79	0.72	0.78	0.12	0.51	0.7	0.06	-0.11
Current Deferred Revenue	0.53	0.6	0.28	0.58	0.69	0.69	0.62	0.47	0.51	-0.07	0.49	0.6		0.78	0.6	0.46	0.55	-0.27	0.71	0.77	0.59	-0.3	0.45	0.68	0.64	0.05
Long Term Debt	0.69	0.69	0.59	0.45	0.62	0.77	0.73	0.67	0.45	0.05	0.65	0.7	0.78		0.77	0.59	0.74	-0.35	0.76	0.98	0.72	-0.21	0.34	0.77	0.41	0.02
Short Term Investments	0.93	0.87	0.91	0.75	0.67	0.64	0.79	0.94	0.76	0.59	0.91	0.8	0.6	0.77		0.86	0.87	-0.77	0.88	0.85	0.89	0.11	0.56	0.88	-0.09	-0.49
Property Plant Equipment	0.98	0.97	0.83	0.73	0.42	0.34	0.49	0.95	0.73	0.76	0.69	0.54	0.46	0.59	0.86		0.87	-0.91	0.87	0.68	0.89	0.22	0.69	0.8	-0.24	-0.63
Deferred Long Term Liab	0.9	0.87	0.81	0.7	0.53	0.48	0.63	0.89	0.69	0.56	0.77	0.65	0.55	0.74	0.87	0.87		-0.77	0.82	0.81	0.84	0.11	0.53	0.8	-0.06	-0.46
Treasury Stock	-0.87	-0.82	-0.8	-0.78	-0.45	-0.23	-0.46	-0.87	-0.78	-0.88	-0.67	-0.55	-0.27	-0.35	-0.77	-0.91	-0.77		-0.78	-0.45	-0.8	-0.53	-0.75	-0.74	0.45	0.61
Net Tangible Assets	0.9	0.92	0.71	0.77	0.71	0.63	0.72	0.85	0.75	0.5	0.73	0.79	0.71	0.76	0.88	0.87	0.82	-0.78		0.78	0.97	0.11	0.73	0.84	0.08	-0.28
Long Term Debt Total	0.78	0.76	0.69	0.55	0.63	0.76	0.76	0.77	0.56	0.19	0.74	0.72	0.77	0.98	0.85	0.68	0.81	-0.45	0.78		0.76	-0.19	0.38	0.81	0.31	-0.17
Capital Surpluse	0.91	0.91	0.79	0.71	0.65	0.6	0.72	0.88	0.71	0.57	0.77	0.78	0.59	0.72	0.89	0.89	0.84	-0.8	0.97	0.76		0.15	0.65	0.81	-0.08	-0.33
Short Long Term Debt	0.2	0.09	0.3	0.22	0.1	-0.32	0.03	0.26	0.25	0.62	0.15	0.12	-0.3	-0.21	0.11	0.22	0.11	-0.53	0.11	-0.19	0.15		0.49	0.26	-0.67	-0.11
Cash And Equivalents	0.68	0.66	0.45	0.75	0.6	0.15	0.42	0.66	0.73	0.63	0.45	0.51	0.45	0.34	0.56	0.69	0.53	-0.75	0.73	0.38	0.65	0.49		0.61	-0.1	-0.31
Net Invested Capital	0.85	0.83	0.74	0.73	0.64	0.57	0.69	0.84	0.71	0.47	0.76	0.7	0.68	0.77	0.88	0.8	0.8	-0.74	0.84	0.81	0.81	0.26	0.61		0.05	-0.25
Net Working Capital	-0.19	-0.05	-0.44	-0.04	0.23	0.4	0.1	-0.27	-0.14	-0.76	-0.16	0.06	0.64	0.41	-0.09	-0.24	-0.06	0.45	0.08	0.31	-0.08	-0.67	-0.1	0.05		0.54
Capital Stock	-0.6	-0.52	-0.62	-0.51	-0.05	0.08	-0.13	-0.63	-0.56	-0.79	-0.47	-0.11	0.05	0.02	-0.49	-0.63	-0.46	0.61	-0.28	-0.17	-0.33	-0.11	-0.31	-0.25	0.54

Click cells to compare fundamentals

About Emergent Biosolutions Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Emergent Biosolutions income statement, its balance sheet, and the statement of cash flows. Emergent Biosolutions investors use historical funamental indicators, such as Emergent Biosolutions's Operating Income, to determine how well the company is positioned to perform in the future. Although Emergent Biosolutions investors may use each financial statement separately, they are all related. The changes in Emergent Biosolutions's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Emergent Biosolutions's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Emergent Biosolutions Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Emergent Biosolutions. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-190.9 M	-181.4 M
Non Operating Income Net Other	-10.5 M	-10 M

Pair Trading with Emergent Biosolutions

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.

Moving together with Emergent Stock

0.7

LLY

Eli Lilly Sell-off Trend

Pair Corr

Moving against Emergent Stock

0.76	IRWD	Ironwood Pharmaceuticals	Pair Corr
0.74	CVS	CVS Health Corp Aggressive Push	Pair Corr
0.73	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.7	COLL	Collegium Pharmaceutical	Pair Corr
0.67	PBH	Prestige Brand Holdings	Pair Corr

The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.

The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Emergent Stock Analysis

When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Emergent Operating Income from 2010 to 2024

Latest Emergent Biosolutions' Operating Income Growth Pattern

Emergent Operating Income Regression Statistics

Emergent Operating Income History

Other Fundumenentals of Emergent Biosolutions

Emergent Biosolutions Operating Income component correlations

About Emergent Biosolutions Financial Statements

Pair Trading with Emergent Biosolutions

Moving together with Emergent Stock

Moving against Emergent Stock

Additional Tools for Emergent Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY